Investors with space in their portfolio for some new additions in July might want to check out the two ASX shares listed below.
That's the view of analysts at Morgans, which have just put buy ratings on both. Here's what it is saying about them:
Capstone Copper Corp (ASX: CSC)
The first ASX share that Morgans is tipping as a buy is copper miner Capstone Copper.
The broker believes that the miner is well-positioned for double-digit earnings growth through to 2030. This is thanks to the strong copper price and its production growth. It said:
CSC is a pure-play copper producer and developer with 5 diversified copper assets in the Americas and significant short and long-term growth opportunities that we forecast will take group copper production to well over ~300ktpa by CY30F. We forecast +14% EBITDA CAGR to CY30F through its pipeline of near-term volume growth and cost efficiencies in what we expect to be a healthy copper price environment. As a result, we expect CSC to garner share price support as it enters a period of transformational growth.
Morgans has initiated coverage on Capstone Copper with a buy rating and $11.50 price target. Based on its current share price of $9.44, this implies potential upside of 22% for investors over the next 12 months.
PeopleIn Ltd (ASX: PPE)
Another ASX share that Morgans is tipping as a buy is PeopleIn. It is an Australian workforce solutions company that provides contracted staffing and human resources outsourcing services to a range of industries.
Unlike Capstone Copper, which is delivering impressive numbers, Morgans highlights that PeopleIn's earnings are at a cyclical low. However, with the company's shares trading on low multiples and a cyclical turnaround on the horizon, it thinks that patient investors should consider an investment. It said:
Back in Apr-25 PPE provided a 3Q25 update with EBITDA for the quarter at $6.3m, down 9% on the pcp. While in FY24, PPE delivered 4Q EBITDA of $9.8m, a benchmark which is unlikely to be beaten in 4Q25, given amongst other factors the timing of Easter. This note sees us adjust down our 4Q25 earnings expectations ahead of the full year result. It remains our expectation that PPE's earnings are bumbling along the cyclical low, whilst the business is also trading at a relatively low PER multiple (8x FY26F). We reiterate our Speculative Buy rating and price target of $1.05/sh, pending a cyclical turnaround (the timing of which remains uncertain).
Morgans has a speculative buy rating and $1.05 price target on its shares. Based on its current share price of 72 cents, this suggests that upside of 46% is possible between now and this time next year.
